The CEO of Chrysler said he took no pay in 2011 and that, based on financial results, the company is now worth $7.5 billion. (Reuters) The Treasury will sell $6 billion of…
Anheuser-Busch InBev NV may buy China’s Kingway Brewery Holdings’ assets. (Reuters) The Department of Justice is expected to widen its probe of mortgage-backed securities. (Reuters) AT&T (NYSE: T) sets new standards that will impose penalties…
The FDA announced today that the use of statins, common among people with high cholesterol, pose problems which were not mentioned on the lables on the drugs before. The agency reported that…
The Pharmaceutical Research and Manufacturers of America (PhRMA) has spoken out against the new 2013 budget proposed by President Obama. PhRMA represents leading pharmaceutical research and biotechnology companies and some of the…
Glencore and Xstrata are in merger talks. (Reuters) A federal mortgage deal with banks over mortgage fraud would give states enforcement power. (Reuters) Sony (NYSE: SNE) expects a $2.9 billion loss. (Reuters) Long-term…
There is going to be some concerning news if you are on birth control pills made by Pfizer Inc. (NYSE: PFE). The drug giant is announcing a product recall of birth control…
Jon C. Ogg All three major indexes opened higher this morning, but the strength didn’t last as the Chicago PMI number failed to meet expectations and came in lower even than last month’s reading. The…
Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company’s guidance may be getting in the way a bit. The drug giant…
Tuesday is going to be full of major earnings reports, two of which are DJIA components. These are not the only major earnings, but ten we will be watching closely are as…
Pfizer Inc. (NYSE: PFE) has received approval from the US Food and Drug Administration to sell its kidney cancer drug, Inlyta, in the US. The drug is expected to generate about $140…
Paul Ausick Jim Cramer has touted several DJIA upside calls in 2012, but on Monday’s MAD MONEY on CNBC Cramer touted Merck & Company, Inc. (NYSE: MRK) as the great pharma outfit with what may…
The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp blows to…
A state appeals court in Pennsylvania has sided with two women who filed suit against drugmaker Pfizer Inc. (NYSE: PFE) claiming that the company’s Prempro menopause drug caused their breast cancers. The…
Paul Ausick For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like Pfizer Inc.…
As each new year replaces the prior year, 24/7 Wall St. looks at the individual targets on all 30 Dow Jones Industrial Average price targets from Wall Street analysts to come up…
